BACKGROUND: Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2-inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies. METHODS: Peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients on clinical trials of ibrutinib (BTK/ITK inhibitor; n = 19) or acalabrutinib (selective BTK inhibitor; n = 13) were collected serially. T cell phenotype, immune function, and CLL cell immunosuppressive capacity were evaluated. RESULTS: Ibrutinib markedly increased CD4+ and CD8+ T cell numbers in CLL patients. This effect was more prominent in effector/effector memory subsets and was not observed with acalabrutinib. Ex vivo studies demonstrated that this may be due to diminished activation-induced cell death through ITK inhibition. PD-1 and CTLA-4 expression was significantly markedly reduced in T cells by both agents. While the number of Treg cells remained unchanged, the ratio of these to conventional CD4+ T cells was reduced with ibrutinib, but not acalabrutinib. Both agents reduced expression of the immunosuppressive molecules CD200 and BTLA as well as IL-10 production by CLL cells. CONCLUSIONS: Ibrutinib treatment increased the in vivo persistence of activated T cells, decreased the Treg/CD4+ T cell ratio, and diminished the immune-suppressive properties of CLL cells through BTK-dependent and -independent mechanisms. These features provide a strong rationale for combination immunotherapy approaches with ibrutinib in CLL and other cancers. TRIAL REGISTRATION: ClinicalTrials.gov NCT01589302 and NCT02029443. Samples described here were collected per OSU-0025. FUNDING: The National Cancer Institute.
BACKGROUND:Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2-inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies. METHODS: Peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients on clinical trials of ibrutinib (BTK/ITK inhibitor; n = 19) or acalabrutinib (selective BTK inhibitor; n = 13) were collected serially. T cell phenotype, immune function, and CLL cell immunosuppressive capacity were evaluated. RESULTS:Ibrutinib markedly increased CD4+ and CD8+ T cell numbers in CLLpatients. This effect was more prominent in effector/effector memory subsets and was not observed with acalabrutinib. Ex vivo studies demonstrated that this may be due to diminished activation-induced cell death through ITK inhibition. PD-1 and CTLA-4 expression was significantly markedly reduced in T cells by both agents. While the number of Treg cells remained unchanged, the ratio of these to conventional CD4+ T cells was reduced with ibrutinib, but not acalabrutinib. Both agents reduced expression of the immunosuppressive molecules CD200 and BTLA as well as IL-10 production by CLL cells. CONCLUSIONS:Ibrutinib treatment increased the in vivo persistence of activated T cells, decreased the Treg/CD4+ T cell ratio, and diminished the immune-suppressive properties of CLL cells through BTK-dependent and -independent mechanisms. These features provide a strong rationale for combination immunotherapy approaches with ibrutinib in CLL and other cancers. TRIAL REGISTRATION: ClinicalTrials.gov NCT01589302 and NCT02029443. Samples described here were collected per OSU-0025. FUNDING: The National Cancer Institute.
Authors: Regina Jitschin; Martina Braun; Maike Büttner; Katja Dettmer-Wilde; Juliane Bricks; Jana Berger; Michael J Eckart; Stefan W Krause; Peter J Oefner; Katarina Le Blanc; Andreas Mackensen; Dimitrios Mougiakakos Journal: Blood Date: 2014-05-21 Impact factor: 22.113
Authors: N G Pakker; D W Notermans; R J de Boer; M T Roos; F de Wolf; A Hill; J M Leonard; S A Danner; F Miedema; P T Schellekens Journal: Nat Med Date: 1998-02 Impact factor: 53.440
Authors: Preetesh Jain; Mohammad Javdan; Franziska K Feger; Pui Yan Chiu; Cristina Sison; Rajendra N Damle; Tawfiqul A Bhuiya; Filiz Sen; Lynne V Abruzzo; Jan A Burger; Andreas Rosenwald; Steven L Allen; Jonathan E Kolitz; Kanti R Rai; Nicholas Chiorazzi; Barbara Sherry Journal: Haematologica Date: 2011-11-04 Impact factor: 9.941
Authors: Marco Ruella; Saad S Kenderian; Olga Shestova; Joseph A Fraietta; Sohail Qayyum; Qian Zhang; Marcela V Maus; Xiaobin Liu; Selene Nunez-Cruz; Michael Klichinsky; Omkar U Kawalekar; Michael Milone; Simon F Lacey; Anthony Mato; Stephen J Schuster; Michael Kalos; Carl H June; Saar Gill; Mariusz A Wasik Journal: Clin Cancer Res Date: 2016-01-27 Impact factor: 12.531
Authors: Joseph A Fraietta; Kyle A Beckwith; Prachi R Patel; Marco Ruella; Zhaohui Zheng; David M Barrett; Simon F Lacey; Jan Joseph Melenhorst; Shannon E McGettigan; Danielle R Cook; Changfeng Zhang; Jun Xu; Priscilla Do; Jessica Hulitt; Sagar B Kudchodkar; Alexandria P Cogdill; Saar Gill; David L Porter; Jennifer A Woyach; Meixiao Long; Amy J Johnson; Kami Maddocks; Natarajan Muthusamy; Bruce L Levine; Carl H June; John C Byrd; Marcela V Maus Journal: Blood Date: 2016-01-26 Impact factor: 22.113
Authors: Emily M McWilliams; Christopher R Lucas; Timothy Chen; Bonnie K Harrington; Ronni Wasmuth; Amanda Campbell; Kerry A Rogers; Carolyn M Cheney; Xiaokui Mo; Leslie A Andritsos; Farrukh T Awan; Jennifer Woyach; William E Carson; Jonathan Butchar; Susheela Tridandapani; Erin Hertlein; Carlos E Castro; Natarajan Muthusamy; John C Byrd Journal: Blood Adv Date: 2019-02-12
Authors: Joanne E Davis; Sasanka M Handunnetti; Mandy Ludford-Menting; Chia Sharpe; Piers Blombery; Mary Ann Anderson; Andrew W Roberts; John F Seymour; Constantine S Tam; David S Ritchie; Rachel M Koldej Journal: Blood Adv Date: 2020-10-13
Authors: Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd Journal: J Clin Invest Date: 2018-11-19 Impact factor: 14.808